January 6, 2021

Boehringer Ingelheim has notified the U.S. FDA it will discontinue the manufacturing of Catapres® (clonidine hydrochloride), a medication approved in the 1970s for use either alone or in conjunction with other medications to treat hypertension (high blood pressure).

Multiple generic versions of Catapres have been available for decades, the oldest being a generic from Actavis Pharma that received FDA approval in 1986. Patients who have been taking brand name Catapres should speak to their healthcare provider about switching to a generic or a therapeutic alternative.

Extended-release versions of clonidine hydrochloride are also available, both under the brand name Kapvay® (from Shionogi, Inc.) and as generics. However, they are indicated only to treat attention deficit hyperactivity disorder (ADHD) and are not approved for hypertension.

January 22, 2021

Lupkynis Approved as First Oral Therapy for Lupus Nephritis

Read More
January 21, 2021

Cabenuva Approved as Once-Monthly Complete HIV Treatment Regimen

Read More
January 19, 2021

Verquvo Approved for Heart Failure

Read More
January 19, 2021

Enhertu Approved for New Gastric Cancer Indication

Read More